Hexarelin vs IGF-1 DES
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Hexarelin
Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin.
Full profileIGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profile| Hexarelin | IGF-1 DES | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Examorelin, EP 23905, MF-6003 | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 |
| Evidence | Preclinical only | Research-stage |
| Dosing range | 50mcg–200mcg mcg, 1–3x daily (cycling recommended to prevent desensitization) | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) |
| Key side effects | Cortisol elevation, Prolactin elevation, Water retention, Increased appetite | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses |
| Cited sources | 1 reference | 2 references |
Key differences
- Evidence level differs: Hexarelin is preclinical only, while IGF-1 DES is research-stage.
- Administration: Hexarelin — Subcutaneous injection, Intramuscular injection; IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect).
- Frequency: Hexarelin is typically 1–3x daily (cycling recommended to prevent desensitization); IGF-1 DES is 1–2x daily, preferably post-workout.
- Research depth: this profile cites 1 source for Hexarelin vs 2 for IGF-1 DES.
How each works
Hexarelin
Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.